Press Release Archive

03.05.2024

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

02.29.2024

Pfizer Oncology Hosts Innovation Day, Highlighting Fully Integrated Organization, Robust Portfolio, and Strategic Priorities to Drive Long-Term Sustainable Growth

02.29.2024

Pfizer Announces Positive Top-Line Data for Full Season Two Efficacy of ABRYSVO® for RSV in Older Adults

02.26.2024

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

02.19.2024

European Commission Approves Pfizer’s VELSIPITY® for Patients with Moderately to Severely Active Ulcerative Colitis

02.15.2024

Pfizer Invites Public to Register for Webcast of Pfizer Oncology Innovation Day

02.12.2024

UT Southwestern collaborates with Pfizer to develop improved RNA Delivery Technologies

02.05.2024

Breaking Barriers in Cancer Care: The American Cancer Society and Pfizer Announce a $15 Million, Three-Year Initiative to Bridge the Gap in Cancer Care Disparities

01.30.2024

Pfizer Reports Full-Year 2023 Results and Reaffirms Full-Year 2024 Financial Guidance

01.26.2024

European Medicines Agency Validates Type II Variation Application for PADCEV® (enfortumab vedotin) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer

01.10.2024

Pfizer Recommends Shareholders Reject the Below-Market Mini-Tender Offer by TRC Capital Investment Corporation

01.09.2024

TIVDAK® Supplemental Biologics License Application Accepted for Priority Review by FDA for Patients with Recurrent or Metastatic Cervical Cancer

01.08.2024

European Commission Approves Pfizer’s TALZENNA® in Combination with XTANDI® for Adult Patients with Metastatic Castration-Resistant Prostate Cancer

01.02.2024

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

12.19.2023

Pfizer Invites Public to View and Listen to Webcast of January 30 Conference Call with Analysts

12.15.2023

PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) Approved by FDA as the First and Only ADC Plus PD-1 to Treat Advanced Bladder Cancer

12.14.2023

Pfizer Declares First-Quarter 2024 Dividend

12.14.2023

Pfizer Completes Acquisition of Seagen

12.13.2023

Pfizer Provides Full-Year 2024 Guidance

12.12.2023

Pfizer Receives All Required Regulatory Approvals to Complete the Acquisition of Seagen

12.11.2023

FDA and EMA Accept Marstacimab Regulatory Submissions for the Treatment of Hemophilia A and B

12.09.2023

Marstacimab Phase 3 Data Presented at ASH 2023 Demonstrate Significant Bleed Reduction in Hemophilia A and B

12.08.2023

European Commission Approves Pfizer’s ELREXFIO® for Relapsed and Refractory Multiple Myeloma

12.05.2023

Arvinas and Pfizer Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®) and Plans to Expand Vepdegestrant Development Program

12.04.2023

Pfizer and Valneva Complete Recruitment for Phase 3 VALOR Trial for Lyme Disease Vaccine Candidate, VLA15

12.01.2023

Pfizer Announces Topline Phase 2b Results of Oral GLP-1R Agonist, Danuglipron, in Adults with Obesity

11.28.2023

Arvinas and Pfizer Announce Updated Vepdegestrant (ARV-471) Data to be Presented at the 2023 San Antonio Breast Cancer Symposium

11.21.2023

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

11.16.2023

Pfizer and Astellas' XTANDI® Approved by U.S. FDA in Earlier Prostate Cancer Treatment Setting

11.02.2023

Pfizer Highlights Scientific Advances from Growing Hematology Portfolio at American Society of Hematology Annual Meeting

11.02.2023

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

11.01.2023

Stanford Medicine Launches New Global Health Scholars Program for African Physicians

10.31.2023

Pfizer Reports Third-Quarter 2023 Results

10.26.2023

Pfizer and BioNTech Announce Positive Topline Data for mRNA-based Combination Vaccine Program Against Influenza and COVID-19

10.20.2023

FDA Approves PENBRAYA™, the First and Only Vaccine for the Prevention of the Five Most Common Serogroups Causing Meningococcal Disease in Adolescents

10.15.2023

Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentation at ESMO Congress 2023

10.13.2023

Pfizer Amends U.S. Government Paxlovid Supply Agreement and Updates Full-Year 2023 Guidance

10.13.2023

U.S. FDA Approves Pfizer’s VELSIPITY™ for Adults with Moderately to Severely Active Ulcerative Colitis (UC)

10.12.2023

U.S. FDA Approves Pfizer’s BRAFTOVI® + MEKTOVI® for BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer

10.05.2023

Pfizer Presents New Data at IDWeek 2023 Highlighting Advances in Prevention and Treatment of Certain Respiratory Illnesses and Other Infectious Diseases

10.04.2023

Pfizer Declares Fourth-Quarter 2023 Dividend

09.22.2023

Pfizer Broadens Portfolio of Respiratory Vaccines Recommended by CDC Advisory Committee with ABRYSVO™ for RSV

09.19.2023

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

09.19.2023

European Commission Approves Pfizer’s LITFULO™ for Adolescents and Adults With Severe Alopecia Areata

09.18.2023

Pfizer Invites Public to View and Listen to Webcast of October 31 Conference Call with Analysts

09.12.2023

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

09.11.2023

Pfizer and BioNTech Receive U.S. FDA Approval for 2023-2024 COVID-19 Vaccine

09.05.2023

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference